One‐year clinical experience on the use of Nintedanib in systemic sclerosis

We reviewed 11 patients with systemic sclerosis‐related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non‐specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnani, Luca, Spinella, Amelia, Testoni, Sofia, Lumetti, Federica, Scelfo, Chiara, Dardani, Lucia, Bajocchi, Gianluigi, Clini, Enrico, Salvarani, Carlo, Giuggioli, Dilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203787/
https://www.ncbi.nlm.nih.gov/pubmed/37229296
http://dx.doi.org/10.1002/rcr2.1120
_version_ 1785045706249076736
author Magnani, Luca
Spinella, Amelia
Testoni, Sofia
Lumetti, Federica
Scelfo, Chiara
Dardani, Lucia
Bajocchi, Gianluigi
Clini, Enrico
Salvarani, Carlo
Giuggioli, Dilia
author_facet Magnani, Luca
Spinella, Amelia
Testoni, Sofia
Lumetti, Federica
Scelfo, Chiara
Dardani, Lucia
Bajocchi, Gianluigi
Clini, Enrico
Salvarani, Carlo
Giuggioli, Dilia
author_sort Magnani, Luca
collection PubMed
description We reviewed 11 patients with systemic sclerosis‐related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non‐specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.
format Online
Article
Text
id pubmed-10203787
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-102037872023-05-24 One‐year clinical experience on the use of Nintedanib in systemic sclerosis Magnani, Luca Spinella, Amelia Testoni, Sofia Lumetti, Federica Scelfo, Chiara Dardani, Lucia Bajocchi, Gianluigi Clini, Enrico Salvarani, Carlo Giuggioli, Dilia Respirol Case Rep Case Series We reviewed 11 patients with systemic sclerosis‐related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non‐specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated. John Wiley & Sons, Ltd 2023-05-23 /pmc/articles/PMC10203787/ /pubmed/37229296 http://dx.doi.org/10.1002/rcr2.1120 Text en © 2023 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Series
Magnani, Luca
Spinella, Amelia
Testoni, Sofia
Lumetti, Federica
Scelfo, Chiara
Dardani, Lucia
Bajocchi, Gianluigi
Clini, Enrico
Salvarani, Carlo
Giuggioli, Dilia
One‐year clinical experience on the use of Nintedanib in systemic sclerosis
title One‐year clinical experience on the use of Nintedanib in systemic sclerosis
title_full One‐year clinical experience on the use of Nintedanib in systemic sclerosis
title_fullStr One‐year clinical experience on the use of Nintedanib in systemic sclerosis
title_full_unstemmed One‐year clinical experience on the use of Nintedanib in systemic sclerosis
title_short One‐year clinical experience on the use of Nintedanib in systemic sclerosis
title_sort one‐year clinical experience on the use of nintedanib in systemic sclerosis
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203787/
https://www.ncbi.nlm.nih.gov/pubmed/37229296
http://dx.doi.org/10.1002/rcr2.1120
work_keys_str_mv AT magnaniluca oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT spinellaamelia oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT testonisofia oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT lumettifederica oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT scelfochiara oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT dardanilucia oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT bajocchigianluigi oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT clinienrico oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT salvaranicarlo oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis
AT giuggiolidilia oneyearclinicalexperienceontheuseofnintedanibinsystemicsclerosis

Ejemplares similares